Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme
- PMID: 22679114
- DOI: 10.6004/jnccn.2012.0072
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme
Abstract
Despite contemporary surgery, image-guided radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) persists or relapses in nearly all patients, and tumors almost always recur locally. Management of recurrent GBM is variable, but approaches include best supportive care, reoperation, reirradiation, and/or systemic therapy. Promising novel therapies include antiangiogenic agents and stereotactic radiosurgery, which have cytotoxic effects on tumor microvasculature. Emerging data suggest the safety and efficacy of bevacizumab and radiosurgery either alone or in combination. This report presents the case of a man with locally recurrent GBM treated with stereotactic radiosurgery and concurrent bevacizumab, and reviews the preclinical and clinical data supporting this approach.
Similar articles
-
Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16. J Neurosurg. 2015. PMID: 25594327
-
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.Front Biosci (Landmark Ed). 2013 Jan 1;18(2):676-84. doi: 10.2741/4130. Front Biosci (Landmark Ed). 2013. PMID: 23276952 Review.
-
Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.J Neurooncol. 2012 Apr;107(2):323-33. doi: 10.1007/s11060-011-0744-9. Epub 2011 Nov 5. J Neurooncol. 2012. PMID: 22057917
-
Gamma Knife Stereotactic Radiosurgery in Combination with Bevacizumab for Recurrent Glioblastoma.World Neurosurg. 2019 Jul;127:e523-e533. doi: 10.1016/j.wneu.2019.03.193. Epub 2019 Apr 4. World Neurosurg. 2019. PMID: 30954746
-
Efficacy and limitations of stereotactic radiosurgery in the treatment of glioblastoma.Neurol Med Chir (Tokyo). 2012;52(8):548-52. doi: 10.2176/nmc.52.548. Neurol Med Chir (Tokyo). 2012. PMID: 22976136 Review.
Cited by
-
Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.J Neurooncol. 2018 Jul;138(3):571-579. doi: 10.1007/s11060-018-2824-6. Epub 2018 Mar 8. J Neurooncol. 2018. PMID: 29520609
-
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.Cancer Manag Res. 2014 Mar 24;6:149-70. doi: 10.2147/CMAR.S54726. eCollection 2014. Cancer Manag Res. 2014. PMID: 24711712 Free PMC article. Review.
-
Antiangiogenic therapy for glioblastoma: current status and future prospects.Clin Cancer Res. 2014 Nov 15;20(22):5612-9. doi: 10.1158/1078-0432.CCR-14-0834. Clin Cancer Res. 2014. PMID: 25398844 Free PMC article. Review.
-
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320. Oncotarget. 2016. PMID: 26575171 Free PMC article. Review.
-
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4. Int J Radiat Oncol Biol Phys. 2018. PMID: 29102648 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical